Find your path to Dennis
93 people in our graph share verified history with Dennis — schools, employers, funds. One of them is your warm intro.
Niall O'DonnellunlockedDennis: together at University of California, San Diego - Rady School of Management (2005–2006)
×6Dennis: together at University of California, San Diego - Rady School of Management
Dennis: together at Zafgen, Inc.
×3Dennis: together at UC San Diego School of Medicine
About
Dennis D. Kim, M.D., MBA, is President and Chief Executive Officer of Xeno Biosciences, a development-stage biotechnology company focused on obesity therapeutics. His prior roles include Chief Medical Officer at CymaBay, Emerald Biosciences, and Zafgen, Senior Vice President of Medical Affairs at Orexigen Therapeutics, Chief Medical Officer at EnteroMedics, and senior management positions at Amylin Pharmaceuticals, where he served as program medical lead for the development of Byetta (exenatide). He completed a fellowship in Endocrinology/Metabolism at the University of California, San Diego, earned an MBA from the UCSD Rady School of Management, and has authored over 50 publications.
Executive at Xeno Biosciences
Intro paths
→
In turn, Dennis can intro founders to Xeno Biosciences's investors below.
Xeno Biosciences's investors · 3
Experience
- Xeno BiosciencesPresident and CEOcurrent2023 — presentSan Diego, California, United States
- CymaBay TherapeuticsChief Medical Officer2021 — 2023Northern California
- EmeraldChief Medical Officer2019 — 2020
- Zafgen, Inc.Chief Medical Officer2011 — 2019Cambridge, MA, USA
- MetaCon, Inc.Principal2011 — 2016Greater San Diego Area
- Orexigen Therapeutics IncSenior Vice President, Head of Obesity/Metabolic Dz2008 — 2011
- EnteroMedicsChief Medical Officer2007 — 2008
- Amylin PharmaceuticalsExecutive Director, Strategic Planning2001 — 2007San Diego, California, United States
- Rush University Medical CenterResidency1996 — 1999
Skills & more
Biotechnology98Clinical Development49Diabetes52Drug Development59Clinical Trials99Medicine18Clinical Research34Medical Affairs29Drug Discovery15Endocrinology24FDA16Biopharmaceuticals32
+10 more
CommercializationLife SciencesMedical DevicesMedical EducationCardiovascular DiseasePharmaceuticsOncologyManaged CarePharmaceutical IndustryCROFrom Dennis's professional profile.
Frequently asked questions
- Who is Dennis Kim?
- Dennis D. Kim, M.D., MBA, is President and Chief Executive Officer of Xeno Biosciences, a development-stage biotechnology company focused on obesity therapeutics. His prior roles include Chief Medical Officer at CymaBay, Emerald Biosciences, and Zafgen, Senior Vice President of Medical Affairs at Orexigen Therapeutics, Chief Medical Officer at EnteroMedics, and senior management positions at Amylin Pharmaceuticals, where he served as program medical lead for the development of Byetta (exenatide). He completed a fellowship in Endocrinology/Metabolism at the University of California, San Diego, earned an MBA from the UCSD Rady School of Management, and has authored over 50 publications.
- Where did Dennis Kim go to school?
- Dennis Kim studied at University of California, San Diego - Rady School of Management (MBA, Business/biotech); UC San Diego School of Medicine (MD, Endocrinology/Metabolism); Chicago Medical School at Rosalind Franklin U-Med & Science (Medical Degree).
Same school
Also attended University of California, San Diego - Rady School of Management31
Niall O'DonnellManaging Director at RiverVest Venture PartnersTakaaki TobaruPartner at Remiges Ventures, Inc.Jonathan BurbaumEntrepreneur-In-Residence at The Innovation SpaceJosh StilingPrincipal, Investment at Anzu PartnersRaj KapanyInvestor at Sand Hill AngelsDenise LongleyManaging Partner and Co-Founder at Longley Capital
+ 25 more
Also attended UC San Diego School of Medicine19
Victoria LewisVenture Professional at Medical Excellence CapitalArthur SuckowInvestor at 82VSBarbara LevyInvestor at DigitalDx VenturesLorenzo LeoniFounder and Managing Director at Ti-VenturesSilke R. SperlingManaging Partner at Catalpa VenturesTravis StilesCEO & Co-founder at Novoron
+ 13 more
Also attended Chicago Medical School at Rosalind Franklin U-Med & Science7
Bridget Martell MA, MDSenior Biopharmaceutical Advisor at Two Bear CapitalTodd BrintonVenture Partner at Sonder CapitalDavid FeinbergExecutive Chairman at Aegis VenturesNeal PatelExecutive Officer, Director at EndoluxeKevin RiddlebergerFounder at Dispatch HealthGuy WeinbergDirector, President and Secretary of Issuer at ResQ Pharma
+ 1 more
Shared employers
Also worked at CymaBay Therapeutics3
Also worked at Zafgen, Inc.7
Brian McVeighVenture Partner, USA at 4BIO CapitalAndrew PerlmanManaging Partner at GreatPoint VenturesAvi GoldbergPartner at GreatPoint VenturesPatrick LoustauPresident and Chief Executive Officer at Granite BioNerissa KreherExecutive Officer at Entrada Therapeutics, Inc.Frank E. ThomasExecutive Officer at Orchard Therapeutics
+ 1 more
Also worked at Orexigen Therapeutics Inc5
Also worked at Amylin Pharmaceuticals14
Joe Cook JrManaging Director at Mountain Group CapitalCurt HerbertsInvestor at Premji InvestDaniel BradburyInvestor at BioBritKevin FinneyChairman, President and CEO at Autobahn Therapeutics, Inc.Derek MaetzoldExecutive Officer, Director at Castle BiosciencesSean KeenanExecutive Officer at Unifi Software
+ 8 more